West Pharmaceutical Services, Inc. (WST)
NYSE:WST
Want to see WST full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.08Last Year’s EPS
1.84Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call reported broad-based, above-expectation Q1 results with strong revenue growth, substantial margin expansion and raised full-year guidance. Key growth engines—HVP components (including GLP-1s), biologics/NovaPure, Annex 1 conversions, and delivery devices—showed robust performance and underpin optimism. Near-term headwinds include a ~$40M CGM contract roll-off in H2, AR-driven cash flow timing effects, ramp-related margin variability and some commodity cost pressure, but management has mitigation plans and a strong balance sheet (including a new $1B buyback). Overall, positive operational execution and upgraded guidance outweigh the manageable challenges.Company Guidance
Strong Revenue and EPS Beat
Q1 revenue of $845 million, up 21% reported and ~15.3% organic year-over-year; Q1 adjusted EPS $2.13, up 47% YOY and ~45% above prior guidance midpoint.
Raised Full-Year Guidance
Full-year 2026 revenue guidance increased to $3.295B–$3.35B and organic growth raised to 7%–9% (from 5%–7%); adjusted EPS guidance raised to $8.40–$8.75 (up ~15%–20% YOY).
HVP Components Outperformance
HVP components (48% of net sales) delivered $409M in Q1 and grew ~22.6% organically; price contributed ~3.5 percentage points to company growth.
GLP-1 Contribution and Continued Growth Tailwinds
GLP-1 HVP components grew significantly and accounted for ~10% of total company sales in Q1; management expects continued growth driven by insurance expansion, regulatory moves, lower drug prices, new indications and orals expanding the market.
Biologics and NovaPure Momentum
Biologics grew 26% organically in Q1 with NovaPure noted as a standout driver for high-value mix shift and new commercial launches contributing to volume and margin expansion.
Annex 1 Upgrade Opportunity
Annex 1-related projects increased sequentially and were up 66% YOY; management expects Annex 1 and HVP conversion to contribute ~200 basis points of revenue growth in 2026 and identified ~6 billion units targeted for conversion.
HVP Delivery Devices Strength
HVP delivery devices (~15% of revenues) up ~27.5% organically in Q1 ($124M), led by SmartDose 3.5 activity and double-digit growth in non-SmartDose products like SelfDose and Crystal Zenith.
West Vantage (Contract Manufacturing) Progress
Contract manufacturing (West Vantage, ~18% of business) grew ~6.2% organically ($151M); new Dublin site fully operational producing commercial product and supporting drug handling expansion.
Margin Expansion and Profitability
Q1 gross margin 35.1% (up 190 bps YOY) and adjusted operating margin 21.4% (up 350 bps YOY); management expects further margin expansion partly from favorable mix, operational excellence and leverage of SG&A/R&D.
Capital Allocation and Balance Sheet Actions
Board authorized $1 billion share repurchase program; Q1 repurchases of 1.2M shares for $298M and $16M in dividends; ended Q1 with $521M cash. Capex of $43M in Q1 and full-year capex guidance maintained at $250M–$275M.
WST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
WST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 23, 2026 | $274.20 | $309.47 | +12.86% |
Feb 12, 2026 | $245.97 | $243.43 | -1.04% |
Oct 23, 2025 | $276.32 | $306.49 | +10.92% |
Jul 24, 2025 | $226.56 | $278.18 | +22.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does West Pharmaceutical Services, Inc. (WST) report earnings?
West Pharmaceutical Services, Inc. (WST) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is West Pharmaceutical Services, Inc. (WST) earnings time?
West Pharmaceutical Services, Inc. (WST) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is WST EPS forecast?
WST EPS forecast for the fiscal quarter 2026 (Q2) is 2.08.
